Avicanna (TSX:AVCN) Accounts Payable & Accrued Expense : C$8.44 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Avicanna Accounts Payable & Accrued Expense?

Avicanna's quarterly accounts payable & accrued expense increased from Jun. 2024 (C$7.04 Mil) to Sep. 2024 (C$8.22 Mil) and increased from Sep. 2024 (C$8.22 Mil) to Dec. 2024 (C$8.44 Mil).

Avicanna's annual accounts payable & accrued expense increased from Dec. 2022 (C$8.60 Mil) to Dec. 2023 (C$9.19 Mil) but then declined from Dec. 2023 (C$9.19 Mil) to Dec. 2024 (C$8.44 Mil).

Avicanna Accounts Payable & Accrued Expense Historical Data

The historical data trend for Avicanna's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna Accounts Payable & Accrued Expense Chart

Avicanna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

10.90

10.95

8.60

9.19

8.44

Avicanna Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															9.19	8.99	7.04	8.22	8.44

Avicanna Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Avicanna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (TSX:AVCN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

AVCNF:USA 0NN:Germany

Address

480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2

Website

https://www.avicanna.com

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

Executives

Sheldon Inwentash	10% Security Holder
Threed Capital Inc.	10% Security Holder
Phillip Cardella	Senior Officer
Aras Azadian	Director, Senior Officer
Davender Sohi	Senior Officer
David White	Director
Kyle Lawrence Langstaff	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Chandra Panchal	Director
Janet Giesselman	Director

Avicanna Headlines

No Headlines